Hinge Bio, Inc. is a privately held development-stage biotechnology company leveraging its proprietary GEM-DIMER platform to design and develop therapeutics leading to better treatment outcomes for patients living with autoimmune, inflammatory, and infectious disease, as well as cancer. The GEM-DIMER technology platform enables the creation of multivalent, multispecific antibody-based therapeutics that are designed to bind their targets cooperatively allowing for dramatically enhanced biological activity and unique functionality.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/15/25 | $30,000,000 | Series A |
InVivium Capital Lightswitch Capital Point72 Ventures Ridgeback Capital Management | undisclosed |
